Table 5.
The SUCRA Probabilities of Antiplatelet Therapies on Efficacy and Safety Outcomes
| Treatment | Stroke Recurrence | Composite Outcome | Intracranial Hemorrhage | Major Bleeding | ||||
|---|---|---|---|---|---|---|---|---|
| SUCRA | Rank* | SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | |
| Aspirin | 0.3551 | 7 | 0.3465 | 8 | 0.3361 | 7 | 0.2136 | 8 |
| Cilostazol | 0.9343 | 1 | 0.9252 | 1 | 0.9718 | 1 | 0.8850 | 1 |
| Clopidogrel | 0.6252 | 5 | 0.5380 | 6 | 0.6487 | 3 | 0.4950 | 5 |
| Dipyridamole | 0.2250 | 11 | 0.2446 | 10 | — | — | 0.8221 | 2 |
| Sarpogrelate | 0.2433 | 10 | 0.2223 | 11 | 0.5538 | 4 | — | — |
| Terutroban | 0.3547 | 8 | 0.3234 | 9 | 0.2025 | 8 | 0.2451 | 7 |
| Ticlopidine | 0.6510 | 3 | 0.6854 | 2 | 0.4496 | 6 | 0.6740 | 4 |
| Triflusal | 0.4551 | 6 | 0.4811 | 7 | 0.6794 | 2 | 0.8096 | 3 |
| Aspirin plus clopidogrel | 0.7033 | 2 | 0.5741 | 4 | 0.1650 | 9 | 0.0064 | 9 |
| Aspirin plus dipyridamole | 0.6321 | 4 | 0.5657 | 5 | 0.4931 | 5 | 0.3492 | 6 |
| Aspirin plus ticlopidine | 0.3208 | 9 | 0.5937 | 3 | — | — | — | — |
SUCRA indicates surface under the cumulative ranking curve.
*
Ranking SUCRA probabilities in order as the best treatment, the second best, the third best, and so on, among the antiplatelet therapies.